合富國際仲裁 獲賠1.85億元大陸檢驗試劑龍頭F-合富（4745）與射波刀原廠Accuracy代理權仲裁案出現新變化，據去年12月10日仲裁結果，合富將獲Accuracy賠償338萬美元（約新台幣1.13億元），而26日新仲裁結果出爐，將原本338萬美元賠償提高至553萬美元（約新台幣1.85億），若順利入帳，可貢獻合富每股稅後純益（EPS）3.19元。美廠Accuracy先前因中止與合富射波刀的業務代理合約，遭合富向位在香港的國際商會國際仲裁院（ICC）提出商業仲裁，去年12月10初判Accuracy片面違約，需賠償合富338萬美元，本月26日終裁則提高賠償金額至553萬美元，較原先提高逾6成。合富股價27日收52元，上漲0.2元。合富原本預期初判338萬美元金額在去年年底入帳，但Accuracy以在訴訟期間以僅支付賠償金利息的方式拖延；不過，由於ICC仲裁結果具實質法律效力，合富可據此向Accuracy所在的美國法院申請強制執行，預期該筆賠償金今年可順利入帳。據了解，合富總計向Accuracy求償8,000萬美元（約新台幣26.8億元），目前仲裁獲賠的553萬美元僅屬部分金額。合富表示，針對本案費用分擔以及其他未決事項，公司將盡最大努力完成後續仲裁程序，以維股東權益，並在最終裁定前，不做任何臆測。 2016/01/27 22:30陳俍任 / 報導
Pages
▼
Thursday, January 28, 2016
台灣加入TPP 公聽會溝通首衝擊 製藥業!
經部TPP溝通專案辦公室 今啟用經濟部貿易局今天下午宣布跨太平洋夥伴協定TPP溝通專案辦公室正式啟用，依據「TPP推案策略總體行動計畫」，各部會將於1月底前完成各面向影響評估初稿，3月底前定稿達成於TPP文本公布後半年內也就是今年5月初，需要完成全面性評估的目標。貿易局官員表示，針對TPP文本初步檢視後，所盤點出的第一波我國法規落差部分，須將在3月底前提出國內相關法規的修法內容，包括與各界利害相關人進行公聽會與溝通，並完成評估及配套措施。而跨太平洋夥伴協定TPP溝通專案辦公室啟用後，及各單位與專家學者討論的機會更多，也能更為直接。貿易局官員表示，由於台灣若要加入TPP，在法規修法內容將是重中之重，因此需要受衝擊的產業討論配套措施且凝聚共識。而專案辦公室將有9人小組進行活動協調，由貿易局進行對外解釋說明。未來將由經濟部參事成為協調人，與政府中央機關聯繫協調，同時再與國會、產業公協會、消費大眾、TPP成員國駐台機構、在台商會，以及各地方政府或是非政府組織與青年校園網路等進行雙向溝通，用容易理解的方式說明。而由於法規修法範圍複雜，受影響範圍廣，中央大學經濟系教授邱俊榮也建議，今年應注意四大方向，包括智慧財產權如學名藥、專利藥等台廠受衝擊大的議題開始搜集意見。由於需要至少兩輪以上的討論，修法後公告也需要60天，因此建議較有爭議的議題需要先討論。同時還有美豬問題，以及環保與勞工團體等，都是社會較有爭議的議題。邱俊榮說，由於修法細節相當多，美國也不會要台灣完全修法完畢後，才會讓台灣上談判桌，但修法程度必須要讓美國感受到「誠意」。 前往udn tv 粉絲團2016/01/27 15:58
聯合骨科 中國事業處份利益0元變更7.335百萬元 (聯貿醫療/聯合醫療/聯陸科貿)
聯合骨科：補充公告從事大陸地區投資之相關資訊 鉅亨網／鉅亨網新聞中心-2016年01月26日 下午22:08 第二條 第51款1.事實發生日:105/01/262.公司名稱:聯合骨科器材股份有限公司3.與公司關係[請輸入本公司或子公司]:本公司4.相互持股比例:N/A5.傳播媒體名稱:不適用6.報導內容:不適用7.發生緣由:原104/11/3~11/16公告從事大陸地區投資之相關資訊，對於本公司處份間接持有之大陸聯貿醫療用品技術(上海)有限公司、聯合醫療儀器有限公司及聯陸科貿（上海）有限公司等三家轉投資公司，將以104年12月31日經會計師查核後公司淨值為移轉價格，處份利益為零元。現今依據(大陸)淄博雙信志遠有限責任會計師事務所出具之聯合醫療儀器有限公司、聯貿醫療用品技術(上海)有限公司及聯陸科貿(上海)有限公司等三家公司審計報告之帳面淨值為此次移轉價格，與本公司會計師簽證之同期財報淨值略有差異，故變更原公告之處分利益為新台幣7,335仟元。8.因應措施:輸入公開資訊觀測站9.其他應敘明事項:無
營收100億年輕新勢力!! 葡萄王曾盛麟
葡萄王今年強攻外銷 EPS拚逾9元 2016年01月28日 04:10 記者杜蕙蓉／台北報導 葡萄王（1707）在三大事業群發酵，法人預估去年每股稅後盈餘將有8元水準，而今年除了事業體同步發威外，積極布局的東南亞和大陸代工訂單亦有斬獲下，全年營收可望有續揚10-15％機會，EPS上看9～9.5元實力。近期又開始進行一波新品廣告的葡萄王，近年在董事長曾盛麟強化的年輕化策略奏效中，營運延續長紅力道，去年第4季營收以20.12億元，創下新高，也正式衝破20億元大關。法人估計，將帶動全年EPS上攻8元水準。不過，由於今年起葡萄王也將開始攤提平鎮新廠及內湖新大樓的資本支出及費用，因此，去年盈餘配發率可能略低於前幾年的逾7成水準。葡萄王主要事業體為葡萄王母公司、上海葡萄王及傳銷子公司葡眾，去年除了上海葡萄王正式虧轉盈外，母公司和葡眾也都展現強勁成長力道。營運表現最為搶眼的葡眾，近四年來會員每年約維持2萬人的成長水準，今年1月中則來到15.9萬人，原本傳銷界認為年營收60億元是產業界的天花板，不過，葡眾則已連續2、3年都已站上該門檻，在成長力持續中，葡眾也正式成為國內僅次於安麗的第二大傳銷商。積極調整營運體質的上海葡萄王，目前定調以代工訂單為主，去年跟上「健康中國」的大趨勢，直銷、微銷新增客戶挹注下，營收年成長7成以上，也順利轉虧為盈。至於台灣母公司，也全力布局外銷市場，目標鎖定大陸與東南亞市場，首批泰國代工訂單已順利交貨，內部不排除透過跨境電商布局大陸新興自貿區。葡萄王近年積極強化新產品的行銷，今年規劃推出3個新產品，該公司由於產能滿載，斥資20億元興建的二座生產基地，其中 ，平鎮新廠產能約為現有中壢廠的1.5至2倍，該廠預計今年上半年取得使用執照，力拚第4季完成搬遷進駐，該廠第一階段設備產能年產值，是以百億元規畫。另外，生物工程中心第一期將興建100噸發酵槽，去年第4季動工， 工期約18～20個月。隨三大事業群發威，法人預期葡萄王今年營收仍有成長10～15％的動能，EPS可望由9元起跳。(工商時報)
余忠仁: 第二代肺癌標靶藥物 優點0.1個月/缺點多3-4倍
癌症治療－肺癌標靶兩代有別 第一代副作用較低 2016年01月28日 04:10 李盛雯／台北報導 肺癌是無聲殺手，死亡率位居癌症之冠，治療上，針對肺癌國內已有「第一代標靶藥物」及「第二代標靶藥物」，如同神奇子彈般，能針對特定腫瘤細胞做攻擊，與傳統治療相比，副作用較低，是肺癌治療上的一大新利器。台灣胸腔暨重症加護醫學會理事長余忠仁說明，目前肺癌標靶藥物，主要針對表皮生長因子受體基因外顯因子19及外顯因子21的突變進行作用；過去，大家認為第二代標靶藥物對於具外顯因子19突變的肺癌在延長疾病控制與生命有較顯著的效果，但對外顯因子21抑制效果，則與第一代標靶藥物差異不大。近期歐洲腫瘤內科醫學會亞洲大會（ESMO Asia, European Society for Medical Oncology Asia）發表的研究報告Lux Lung 7指出，針對非小細胞肺癌比較「第一代標靶藥物」及「第二代標靶藥物」的效果進行評估；其中，「第二代小分子標靶藥物」雖與腫瘤的結合性較高、藥效較強，但副作用明顯較多，提供醫界一項參考依據。余忠仁解釋，臨床研究結果顯示，「第二代標靶藥物」相較「第一代標靶藥物」，其患者中位無惡化存活期(median PFS ,Progression-free Survival)多出約0.1個月，但副作用較顯著，患者出現嚴重全身性痘瘡、皮疹及甲溝炎等症狀的發生率約為「第一代標靶藥物」的3到4倍。余忠仁說明，正因如此，在選擇標靶用藥時，務必進一步評估患者對於副作用的耐受力，若無法承受，或許可考慮使用「第一代標靶藥物」治療，來維持良好的生活品質與治療成效。研究結果顯示，「第二代標靶藥物」對於疾病控制時間稍不如預期的長，副作用上較「第一代標靶藥物」如預期中的顯著。對此，余忠仁提醒，其實兩代標靶藥物的特性不同，療效與副作用也不同，患者可在事前與醫師做充分討論，考慮是否願意承受較大的副作用以換取稍長的存活，醫師也可依據個人病情，來選擇適當標靶用藥，達成最佳的治療效果。(中國時報)
安成藥 養小金雞(安成生技2016Q3-4興櫃) /Megace推營收4.34億
安成藥報捷 營運看俏 2016-01-28 02:22 經濟日報 記者黃文奇／台北報導 安成藥（4180）三項產品上膛，新藥子公司蓄勢待發。安成藥旗下有三項學名藥產品等待取證中，包括抗帶狀疱疹神經痛Lidoderm、抗高血壓與心絞痛Cardizem、抗胃食道逆流的Dexilant，今年有望進入銷售產品列車中，搶攻25億美元市場。安成藥除了三項學名藥有機會在今年取證，新藥子公司安成生技隨也規劃下半年公開發行並登錄興櫃，以當前進度來看，安成生技未來有機會成安成藥的小金雞。安成藥昨（27）日股價收152元，下跌3元。安成藥自創辦人陳志明回台後，一直是資本市場的焦點，去年該公司有四項學名藥產品上市，寫下台灣生技公司新猷，同時也是首家成功挑戰P4（Paragraph IV）學名藥法規的台灣公司。安成藥去年拿下抗AIDS患者惡病體質Megace ES首仿資格，取得180天學名藥銷售專屬權，推升全年營收4.34億元，年成長23.3%，而Megace E學名藥損害賠償可能延至今年上半年入帳。安成藥近年共送出11張學名藥藥證申請，法人預估，Lidoderm、Cardizem、Dexilant的三項學名藥有機會在今年取得。
安成藥(4180)三大學名藥拼今年上市，子公司安成生技下半年登興櫃 財訊新聞 2016/01/27【財訊快報／何美如報導】安成藥(4180)現已有四項藥品上市銷售，隨美國銷售團隊重整，通路拓展效益漸顯，今年業績貢獻將加大，外界也預期，治療帶狀泡疹神經痛Lidoderm、高血壓與心絞痛Cardizem、胃食道逆流Dexilant的三項學名藥有機會在2016年取得藥證，帶動營運登高峰。而子公司安成生技隨新藥開發向前跨步，也規劃下半年公開發行並登錄興櫃，將成安成藥的小金雞。去年共四項藥品陸續上市的安成，由於AIDS患者惡病體質Megace ES為第一家上市學名藥，具180天的銷售專屬權，上市後成為旗下藥品綑綁銷售重要利器，推升下半年營收較上半年成長將近一倍，全年營收4.34億元，年成長23.25%，由於Megace E學名藥的損害賠償可能趕不及去年第四季入帳，預估單季維持小虧。美國銷售團隊去年底才完成重整，需更多時間去拓展通路，且各產品市場競爭情況不同，內部預估，藥品上市後約需要半年到一年才能達銷售高峰，去年取得得四項藥品在今年的業績貢獻將逐步加大。過去幾年安成藥共送出11張ANDA藥證申請，法人預估，治療帶狀泡疹神經痛Lidoderm、高血壓與心絞痛Cardizem、胃食道逆流Dexilant的三項學名藥有機會在今年取得，美國市場合計近25億美元。市場高達10.4億美元的Dexilant學名藥，已與原廠Takeda和解，獲授權以Takeda學名藥廠商銷售，自行生產之Dexilant學名藥則可在第一家學名藥上市後180天上市。Lidoderm市場高達12.85億美元，儘管已有2家學名藥上市，也有機會搶下相當市占率。而Cardizem屬 高技術門檻學名藥，美國市場約2.37億元，法人預估，有機會在上半年上市。至於發展新藥的子公司安成生技，安成藥持股85%，目前資本額5.6億元，隨著藥品開發至一定階段，內部已規劃，下半年辦法公開發行及登錄興櫃。治泡泡龍的AC-203，亞洲外之全球市場已專屬授權予Marathon之衍生製藥公司Castle Creek(CCP)，預計今、明年分別在國內、外進入臨床試驗。治痛風/關節炎的AC-201已在台美進行二期臨床試驗，預計年底完成。而適應症為癌症標靶治療引起的皮膚副作用的AC-701，已於台灣完成二期臨床試驗。骨關節炎新藥骨瑞寧口服膠囊近期已向TFDA提出新藥上市許可申請。
彥臣 腦癌新藥HDAC8 inhibitor 科專費用3770萬 18個月拚IND
彥臣新藥 將申請美臨床 2016-01-28 02:22 經濟日報 記者黃文奇／台北報導 彥臣生技（4732）昨（27）日表示，旗下獲得經濟部補助的「抗腦癌新藥專一性HDAC8抑制劑」開發計畫，最快今年底明年初向美國食品藥物管理局（FDA）申請進入人體臨床試驗（IND）。彥臣說，該開發計畫時程計18個月，預計投入總經費3,770萬元，並由財團法人資訊工業策進會補助1,185萬元，約占總經費31.4%。彥臣開發的「抗腦癌新藥專一性HDAC8抑制劑原料藥試量產及臨床前試驗計畫」，去年中即獲得獲經濟部科專補助1,185萬元，去年中正式獲得補助，若一切順利，今年底可望完成計畫。該次計畫中，彥臣說，除委託PIC／GMP之原料工廠進行小量試生產外，將同時完成劑型設計與毒理等臨床前試驗，下一步則是向美國FDA申請人體臨床。彥臣的新藥產品是熱門標靶抗癌藥物「HDAC抑制劑」，是新專利化合物BMX，至目前為止已經取得中國大陸、俄羅斯、台灣、美國、日本、歐盟、澳洲等專利。
TFDA強化 阿拉伯樹膠 規格要求
預告修正「食品原料阿拉伯樹膠衛生標準」草案 資料來源：食品藥物管理署建檔日期：2016/01/27 更新時間：2016/01/27衛生福利部(下稱衛福部)於本(27)日辦理第二次預告修正「食品原料阿拉伯樹膠衛生標準」草案，名稱並修正為「食品原料阿拉伯樹膠規格標準」，該草案係參酌國際相關規格，修正阿拉伯樹膠之定義、性狀描述、鑑定及純度等之要求，以保障相關原料之衛生安全及品質；該草案將進行為期60天之評論期，以蒐集各界意見。 阿拉伯樹膠具有乳化、穩定及增稠之功能，於糖果、糕點、飲料等食品加工用途廣泛，為我國及世界各國食品工業中普遍使用，鑒於該原料植物來源品種及加工方式之不同，其性狀亦有所改變，爰國際間於近年內均已就其規格進行修正。為使我國相關標準符合國際趨勢，衛福部前經參酌美國食品化學法典(簡稱FCC)之最新規格進行修正，並於104年9月23日以部授食字第1041303359號公告預告，惟因預告後接獲各界之修正建議，及另行參酌國際組織JECFA及歐盟等之規格要求，故重新就阿拉伯樹膠之定義及性狀(包括成分組成、水解產物、原料呈色及商業化型態等)提出更為明確之規格要求，並增訂微生物限量及加嚴重金屬鉛之限量，以供食品業者遵循。
Wednesday, January 27, 2016
長庚醫院 張健宏: 機械微創取出血栓 治療急性中風
急性缺血性腦中風新療法 突破黃金治療3小時 2016-01-2614:39 〔記者林彥彤／台北報導〕救護車聲響，一名79歲的郭老先生昏迷且左邊肢體無力，經醫師診斷後發現右側內頸動脈及中大腦動脈嚴重阻塞，家屬決定接受「介入性動脈機械取栓法」，術後3個月恢復正常，目前僅有左手輕度活動不靈活，是長庚醫院執行介入性動脈機械取栓法的成功首例。 介入性動脈機械取栓法突破過去靜脈注射血栓溶解劑的侷限，針對中風發病超過3小時的病患透過導管技術，從微創口經動脈導引到阻塞的腦血管前端，再判斷是否應該取出血栓或是打通阻塞血管。長庚醫院腦血管科主任張健宏醫師說，腦部側枝循環的好壞是影響患者術後恢復的關鍵，而新技術治療則是延長治療急性中風的搶救黃金時間達12小時內。 醫師提醒，中風又被稱為沉默的重症。民眾應提早察覺中風症狀，如嘴歪眼斜、體無力、麻木、言語不清、構音障礙、大小便失禁和意識模糊甚至昏迷等。此外具有高血壓、心臟病、糖尿病和高膽固醇等慢性病患者平時要按時服藥，並注意冷熱溫差的改變。家屬若發現患者出現中風情形，一定要趕緊撥打119，若經評估後符合治療條件務必即時做出決定，才可避免肢體癱瘓等嚴重後遺症。 目前長庚醫院結合各科成立整合性急性腦中風治療小組，搶救中風患者的診斷及治療時間。介入性動脈機械取栓法的案例截至去年也已完成近50例，長庚醫院重症神經外科主治醫師王以舟說，今年2月1日健保也已將支架取栓費用納入，但患者是否適用手術還需待醫師團隊評估。
Athenex口服Docetaxel 進入IND (藥華Oraxol口服紫杉醇/ Oratecan口服喜樹鹼)
Athenex宣佈美國FDA批准Oradoxel的新藥臨床試驗申請 2016年01月26日 下午02:26紐約州 布法羅和香港2016年1月26日電 /美通社/ -- Athenex, Inc.今天宣佈，該公司已經獲得了美國食品藥品監督管理局（美國FDA）對繼續進行其自主研發的口服型多西他賽的臨床研究的批准。此次獲准繼續研究讓 Athenex 第六次向美國 FDA 成功提交了腫瘤新藥臨床試驗申請(IND)（這六次申請分別涉及五種口服抗癌藥和一種藥膏），這也預示著該公司的口服吸收平臺將推出第三種此類臨床候選藥物。多西他賽是一種成熟有效的高效能抗癌藥物。Athenex 已經為其開發了名為「Oradoxel」的口服型藥物。相應的 Athenex 腫瘤口服吸收技術以自主研發的 P-糖蛋白(Pgp)泵抑制劑（「Orascovery」平臺）為基礎，而這種泵抑制劑源自於Athenex 從商業合作夥伴 Hanmi Pharmaceuticals（韓美藥品）那裏獲得的獨家授權，2011年，Athenex獲得了相關技術在全球各主要地區的授權，但 Hanmi Pharmaceuticals 保留在韓國和日本地區進行開發的權利。Athenex 目前擁有處於晚期臨床研究階段的口服型紫杉醇和伊立替康，這些藥物在更早的臨床評估中展現出了頗有開發前途的特性。 Athenex 臨床開發和監管事務副總裁 Douglas Kramer 博士表示：「我們的團隊為 Oradoxel 向 FDA 提交了超過35,000頁的綜合 IND 資料，包括關於我們口服吸收平臺的信息。我們的 Pgp 泵抑制劑被證明能幫助提升知名腫瘤藥物的口服吸收水平，而如今這些藥物只能通過靜脈注射的方式向病人提供。我們現在很高興能夠創造無限的可能性，在幫助更多的癌症病人上面有一番作為。」 Athenex 臨床藥理學副總裁 Gerald Fetterly 博士補充說：「我們已經在臨床上瞭解到，將現有的靜脈注射高效能腫瘤藥物轉變成口服形式，可以為優化多種多樣的病人給藥方案開啟大門，而這些方案是不可能通過靜脈注射來實現的。以口服形式給藥能讓病人在更長的時間裏吸收活性強效藥物成分，臨床研究也表明在藥代動力學方面，口服型藥物在血液中的含量能達到預期，與靜脈注射形式相比，這樣臨床效果好，不良副作用也較少。」 Athenex 主席兼行政總裁 Johnson YN Lau（劉耀南）博士（擁有內外全科醫學士(MBBS)學位，並且是英國皇家內科醫師學會會員(FRCP)）則評論說：「我要祝賀我們的 Athenex 香港團隊和 Athenex 美國團隊，並且要感謝我們的合作者協助我們開展這個項目，達到了這一具有重要意義的成功監管里程碑。Oradoxel 項目最初由 Athenex 香港團隊在香港理工大學(The Hong Kong Polytechnic University)應用生物及化學科技學系(ABCT)的鄭家純藥物研發實驗室(Henry Cheng Research Laboratory)開發，這個項目還獲得了香港創新科技署(Hong Kong Innovation and Technology Commission)的 SERAP（小型企業研究資助計劃）等額撥款的部分支持。現在應該祝賀香港成為了面向全球癌症病人的重要藥物開發科學創新基地。我們所取得的這一成就還幫助加強了我們業務策略的成功實施，即在中國和美國之間搭建一座醫療科技的『橋樑』。」 除了公司業務所覆蓋的主要區域之外，Athenex 現在還和 Orascovery 平臺的發起者 Hanmi Pharmaceuticals，一起在韓國和日本開發 Oraxol 與 Oratecan，並和 PharmaEssentia（藥華醫藥股份有限公司）與 ZenRx 分別在臺灣和新加坡地區與新西蘭和澳洲地區進行開發。
Athenex, Inc.簡介 Athenex 創立於2003年，是一家全球專業腫瘤醫藥公司，主要關注新一代癌症疾病療法和支持療法的商業化開發。Athenex致力於提供能大大改善癌症病人的病情的創新藥物。我們的業務包含十種正在開發的自主研髮型創新藥物、醫療科技創新中心、產品開發團隊，以及跨越中國與北美的獨一無二的新興製造供應鏈。我們的雇員包括幾百名具有奉獻精神的專業人員，他們致力於達成改善全球癌症病人的生活的使命。憑藉我們主要集中於中美兩國並相互聯繫的創新、開發與製造事業，我們能在不同的大陸和多個監管環境中發現、開發和提供自主研發的醫療技術。我們已經在紐約州布法羅和克拉倫斯、新澤西州克蘭福德、香港、臺灣臺北及中國內地重慶市內的多個地點設立了辦事處。除了我們的辦事處之外，我們還在新西蘭但尼丁、香港、中國內地的廣州、韓國首爾、臺灣的臺北、危地馬拉的危地馬拉城與阿根廷布宜諾斯艾利斯擁有地區層面的開發合作夥伴。
Reference: 藥華 開發 Oraxol(口服紫杉醇)/ Oratecan(口服喜樹鹼) (licensed by Kinex)
Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel Buffalo, NY and Hong Kong- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex's sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer drugs, one ointment) and the third such clinical drug candidate in Athenex's oral absorption platform. Docetaxel is an established and effective high potency anti-cancer drug. Athenex has developed an oral form, called Oradoxel. The Athenex oncology oral absorption technology is based on a proprietary P-glycoprotein (Pgp) pump inhibitor ("Orascovery" platform) licensed exclusively from our business partner, Hanmi Pharmaceuticals, in 2011 for all major worldwide territories except Korea and Japan that were retained by Hanmi Pharmaceuticals. Athenex currently has the oral forms of paclitaxel and irinotecan in later stage clinical studies, which showed promising profiles in earlier clinical evaluations. Douglas Kramer, MD, Athenex Vice President of Clinical Development and Regulatory Affairs stated "Our team submitted to the FDA a comprehensive IND package for Oradoxel of over 35,000 pages, including information on our oral absorption platform. Our Pgp pump inhibitor has been demonstrated to enhance the oral absorption of well-known oncology drugs that today are only available to patients as intravenous medicines. We are excited for the possibilities to make a difference in helping more cancer patients." Gerald Fetterly, PhD, Athenex Vice President of Clinical Pharmacology added "We have learned in the clinic that converting existing intravenous high potency oncology drugs into oral forms opens the door to optimizing a wide array of patient dosing regimens which cannot be achieved with IV. Oral forms of dosing allow the patients to be exposed over a longer period of time to the potent active pharmaceutical ingredients and clinical studies have shown expected pharmacokinetic blood levels of exposure; leading to good clinical efficacy with less adverse side effects compared with the intravenous counterparts." Athenex Chairman and CEO Johnson YN Lau, MBBS, MD, FRCP, commented, "I want to congratulate both our Athenex Hong Kong team and the Athenex US team, and thank our collaborators on this project on achieving this important successful regulatory milestone. The Oradoxel project was initially developed by the Athenex Hong Kong team in the Henry Cheng Research Laboratory for Drug Development, Department of Applied Biology and Chemical Technology (ABCT), The Hong Kong Polytechnic University and this project was also partially supported by a SERAP matching grant from the Hong Kong Innovation and Technology Commission. Hong Kong should be congratulated as an innovator of important drug development science for cancer patients globally. This accomplishment also reinforces the successful execution of our business strategy creating a medical technology bridge between China and the United States." In addition to its primary territories, Athenex is also developing Oraxol and Oratecan with Hanmi Pharmaceuticals, the originator of the Orascovery platform, in Korea and Japan, with PharmaEssentia in Taiwan and Singapore, and with ZenRx in New Zealand and Australia.
About Athenex, Inc. Founded in 2003, Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes 10 innovative proprietary products under development, medical technology innovation centers, product development teams and a unique emerging manufacturing supply chain across both China and North America. Our employees include several hundred dedicated professionals to the mission of improving the lives of cancer patients throughout the world. With our connected innovation, development and manufacturing presence concentrated in China and the US, we can identify, develop, and deliver proprietary medical technology across continents and multiple regulatory environments. We have offices in: Buffalo and Clarence New York, Cranford New Jersey, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China. In addition to our offices, we have regional development partners in Dunedin New Zealand, Hong Kong, Guangzhou China, Seoul South Korea, Taipei Taiwan, Guatemala City, Guatemala, and Buenos Aires Argentina. Any opinions, findings, conclusions or recommendations expressed in this material/event do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the Small Entrepreneur Research Assistance Programme (SERAP) Project Assessment Panel.
Athenex Leadership Team
Athenex is led by an experienced global team in pharmaceutical drug development.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman, Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Flint D. Besecker, CPA Chief Operating Officer & Board Director, Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
Rudolf Kwan, MBBS, MRCP Chief Medical Officer, Rudolf has had a successful career in the pharmaceutical industry with over twenty years of experience in global clinical development and operations. Before joining Athenex, he served dual roles at Schering-Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS. In the clinical operations position, Rudolf successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific for Schering-Plough. As Vice President of Global Clinical Development, CNS, he was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration. He also designed and executed multiple global development programs. Earlier at Schering-Plough, Rudolf held various clinical operation positions with increasing responsibility. He held similar positions at Chiron Corporation and at Smith Kline Beecham. Rudolf obtained his medical degree in Hong Kong and did subsequent training in England. He is a member and Chair of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse of the National Institute of Health in the USA (NIH). He is also a member of several advisory panels and grant review panels for NIH.
David Hangauer, PhD Chief Scientific Officer, David is a leader in the field of structure based drug design. Following doctoral studies in chemistry at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories, where he directed a variety of drug discovery projects. In 1989, he returned to academia and joined the chemistry faculty at SUNY at Buffalo, where he has had a productive career that has focused on developing protein kinase inhibitors. David's expertise has been sought by pharmaceutical and biotechnology companies worldwide, including: Lederle/Wyeth-Ayerst Research Laboratories; New Medical Technologies; Sphinx/Eli Lilly Pharmaceuticals Inc.; Yuhan Corporation; Periodontix, Inc.; ICAgen, Inc.; ARPIDA, Scientific Advisory Board & Founding Scientist; and Signal Pharmaceuticals, Inc. Most notably, he led the chemistry effort at Hypnion, Inc., which was sold to Eli Lilly in 2009 for more than $300 million. The company's major asset was an insomnia drug that was designed and discovered under the leadership of David.
Wing-Kai Chan, MD, MBBS, FRACP Head of Asia / Pacific Clinical , Wing-Kai's roles have included Director, National Center of Excellence for Clinical Trial and Research at the National University Hospital, Taiwan, and Medical Director in Roche Asia/Pacific and in that capacity, participated in the clinical development of a number of anti-cancer drugs such as: Rituxan, Herceptin and Xeloda, to name a few. Wing-Kai is a medical graduate of the University of New South Wales, Sydney, Australia and a Fellow of the Royal Australian College of Physicians. He is also a member of American Society of Clinical Oncology. Wing-Kai has authored many publications in clinical oncology over the course of his distinguished career. Wing-Kai is based in Taipei, Taiwan and Hong Kong.
William ZuoWilliam Zuo, PhD President of Polymed Therapeutics, William has over 21 years of experience in pharmaceutical business, and specializes in the manufacturing, sale and marketing of various complex "Active Pharmaceutical Ingredients." William received his PhD in Nanotechnology from Rice University.
Teresa Bair, ESQ Senior VP of Corporate Development & Legal Affairs Teresa is a seasoned commercial attorney who has extensive experience handling complex business matters in both the board room and court room. Prior to joining Athenex, she served as a partner at Harris Beach PLLC, a nationally recognized law firm. Teresa successfully represented business clients, including Fortune 500 companies, in matters involving mergers and acquisitions, intellectual property, international law, equity investments, corporate governance, and contract transactions. Teresa has been consistently recognized by peer journals as a "Super Lawyer" in Business Litigation and Intellectual Property. Teresa received her law degree (JD) from University at Buffalo School of Law, and a Bachelor of Science in Business Administration from Bowling Green State University.
Stephen Yeung, CA Chief Business Officer – Asia Pacific, Stephen is a seasoned financial professional with a proven track record of over 35 years of leadership experience in accounting, treasury, corporate finance, business and project development and management in direct and private equity investments, private family wealth and fund management. After launching his career in Canada with the largest multinational oil conglomerate in the country, Stephen relocated to the company's Asia Pacific regional head office in Hong Kong. Capitalizing on the significant economic growth in Greater China in the 1980's, Stephen moved into investment banking/corporate finance; direct, private equity, and private family fund investment development and management; all with large local corporations and local listed companies in Hong Kong, including a fortune 500 group. He holds a Bachelor of Arts in Mathematics and Accounting from St. John's University, Minn., USA, and a Master of Business Administration in Finance from The University of Toronto, Ont., Canada. He is also a Chartered Accountant registered with the Province of Ontario in Canada.
Benjamin Lee, PharmD, Hong Kong Research & Product Development Leader, Benjamin is the President of Comprehensive Drug Enterprises Ltd, an award winning, technology-driven company that provides innovative solutions for drug delivery system. Founded in 2005 and located in HK Science Park, it has products from the pre-clinical to the clinical stage of development. Benjamin was also an adjunct member of the Faculty of Medicine at the Chinese University in Hong Kong School of Pharmacy. He holds a Doctorate from the University of Kentucky College of Pharmacy. He trained under Drug Development and Clinical Research Fellowships at Glaxo Wellcome and the University of North Carolina, School of Pharmacy. Upon completion of his Fellowships, Benjamin joined Glaxo Wellcome as a Senior Research Scientist, rising to Lead Scientist and group manager in Clinical Development Center at GlaxoSmithKline. He has participated in the development of several of the GlaxoSmithKline respiratory drugs development, regulatory approval and marketing; and has also participated in product development and registration in neurology and pain management.
Tracey Burr, PhD, Chief Scientific Officer, Active Pharmaceutical Ingredients, Tracey has been engaged in leading product development, portfolio management and lifecycle management for nearly 20 years, including over 10 as a successful executive in the international pharmaceutical industry. Tracey is the CSO of our API manufacturing platform, with significant pharmaceutical product and regulatory experience in worldwide markets. She has been instrumental in successfully filing numerous ANDA/NDAs/Dossiers and has actively contributed to the development of over 20 products through the drug development process, from target identification, R&D, regulatory approval, product launch and post-commercialization support. Under her leadership, pharmaceutical companies have seen dramatic increases in R&D scope, regulatory approvals, sales, and global production. She now brings her characteristic combination of discipline, vigor and vision to the development and commercialization of Athenex products. Prior to joining Athenex as CSO, Tracey worked for 15 years as a CSO for pharmaceutical companies in the USA, China, Switzerland and Germany. Tracey received an MSc in Organic Chemistry from the California Institute of Technology (Caltech), and a PhD at the Massachusetts Institute of Technology (MIT) in Materials Science and Engineering.
Stephen A. Panaro, PhD QuaDPharma, President, Stephen has over 12 years of experience in the pharmaceutical industry. His experience spans from drug discovery and API synthesis, to large-scale commercial production of finished products across many different dosage forms and packaging configurations. Throughout his carrier, Stephen has overseen personnel in nanotechnology, quality control (QC) chemistry, QC microbiology, customer service, project management and production, to name a few. Most recently, Stephen founded QuaDPharma based on his experience with clinical and commercial manufacturing. He wanted to create a company unlike the large-scale contract manufacturing organizations of today and focus on projects, and products, that require small to mid-scale manufacturing. The clients that sponsor these products require a unique blend of customer service and technical expertise. QuaDPharma provides just the right environment for development and commercialization of these innovative pharmaceutical products.
Board of Directors The Athenex Board of Directors is composed of carefully selected professionals who bring a wealth of governance and global corporate experience.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
Board of Directors The Athenex Board of Directors is composed of carefully selected professionals who bring a wealth of governance and global corporate experience.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
Athenex Board of Directors
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
生展 陳威仁 解除競業禁止
生展生技：本公司董事會決議通過解除經理人競業禁止 鉅亨網新聞中心 2016-01-26 18:16:10 第三十四條 第22款1.董事會決議日期:105/01/26 2.許可從事競業行為之經理人姓名及職稱:陳威仁/總經理3.許可從事競業行為之項目:在無損及本公司利益解除經理人競業禁止限制。4.許可從事競業行為之期間:任職本公司經理人期間。5.決議情形（請依公司法第32條說明表決結果）:出席董事均無異議通過。6.所許可之競業行為如屬大陸地區事業之營業者，經理人姓名及職稱（非屬大陸地區事業之營業者，以下欄位請輸不適用）:不適用。7.所擔任該大陸地區事業之公司名稱及職務:不適用。8.所擔任該大陸地區事業地址:不適用。9.所擔任該大陸地區事業營業項目:不適用。10.對本公司財務業務之影響程度:不適用。11.經理人如有對該大陸地區事業從事投資者，其投資金額及持股比例:不適用。12.其他應敘明事項:無。
奇美全人醫療 建置 急診安寧團隊
臨終照護最後一哩路 奇美醫率先有急診安寧團隊 NOWnews 2016/01/26 記者黃芳祿／台南報導奇美醫學中心急診安寧團隊由急診醫護人員受訓後成立，減少照會的繁瑣程序及等待，更直接地在第一時間給予病人適當的安寧療護。提升急診醫護人員對安寧的認識及理念，帶動台灣急診安寧療護。奇美醫學中心全人醫療科主治醫師翁子傑表示，當疾病進展至末期，病人遭遇身體上的不適，常常送至急診尋求醫療上的協助，緩解症狀以及心中的焦躁不安，但是，安寧療護在急診的推動是充滿阻力的。急診醫師很忙，沒有時間好好坐下來了解病人及家屬的需求。急診醫師在短時間內無法和病人及家屬建立良好的醫病關係，也無法在短時間內與病人談論到生死的議題。安寧療護不適合急診室嗎？奇美醫學中心在101年8月開立全人醫療科，以整合醫療(Holistic)的模式，照顧急診室住院待床病人同時將安寧療護帶入急診室，開啟了急診安寧療護照護模式。另外奇美醫學中心急診醫學部積極培育急診安寧人員，包括醫師及護理師，目前有兩位全人醫師取得安寧專科醫師，另有兩位急診醫師完成安寧醫師訓練，奇美醫學中心的急診住院醫師訓練亦需至安寧病房接受緩和醫學訓練一個月。目前已有兩位護理師完成安寧療護護理師訓練，並且成為安寧種子，於急診持續推廣安寧療護。 急診安寧服務的對象為急診病人，及早發現病人有安寧需求，除了原本的醫療外，醫療團隊也積極介入安寧療護，提供病人身體上的舒適醫療，讓病人家屬了解目前的醫療目標，達到安心目的。
中國阿膠2千噸疑慮 (驢皮/馬皮/騾皮 ?)
中國補品阿膠 市場4成偽原料 2016年01月27日【記者李源／綜合報導】在中國流傳已久的知名補血聖品「阿膠」，原是以驢皮熬製，但近日被曝出有近四成阿膠是由馬皮、騾皮、豬皮，甚至是工業用皮等替代原料製成。據中央社引述陸媒報導，有業界人士指出，以原料驢皮供應計算，阿膠年產量應只能生產3千噸，但目前市場銷量卻高達5千噸；意味市場有近四成的阿膠是由假冒原料製成。業界人士透露，一張驢皮要價2千至3千元（人民幣，以下同，約合新台幣1萬至1萬5千元），而一張馬皮、騾皮僅價值200元，豬皮和一些製作皮鞋、皮包所剩餘的坯料當然就更便宜。由於眾多不法業者製作假阿膠，也造成中國大陸市面上的產品價格相差甚遠，從每公斤400至4千元都有。若想買阿膠來補身的朋友，請眼睛睜大，不要貪便宜，以免買到仿冒品，因小失大。
新藥代號與股價聯結 (解盲股價)??!!
新藥代號有意思？ 法人解盲 浩鼎拚822元 2015年12月02日 04:10 記者杜蕙蓉／台北報導 銳不可當的生醫股，昨日持續引領風騷，法人以熱門新藥公司的新藥名稱解讀股價密碼，認為浩鼎（4174）乳癌新藥OBI-822的代號、中裕（4147）TMB-355的數字都暗藏玄機，本波2檔指標股攻勢，第一波火力將分別上看822元、355元。不過，由於昨日生醫股的成交量已有稍微降溫跡象，店頭生醫股在上櫃成交占比從過去的逾5成，昨日已降至40.14％，成交金額137.71億元，也較5日均量150.8億元偏低，生醫股是否還能天天狂飆，備受關注。已經讓股民看傻眼的生醫股，每天大演的爆熱行情，已引爆話題，生技何時會回檔？現在可以進場嗎？浩鼎、中裕要漲到何時？有趣的是，儘管市場不斷喊生醫股瘋了，浩鼎、中裕漲的太離譜，但昨天新科生技股王浩鼎盤中曾大漲9％，以741元再創新天價，而中裕則直奔漲停，以235元作收，不落人後的智擎也上漲7元，以278元收盤。另外，健亞、中裕、中天、智擎、晟德、東洋、南光、大江、盛弘交投也十分熱絡，擠身店頭股成交量前30名排行榜，而儘管法人已有調節浩鼎、健亞、中天、邦特現象，但東洋、晟德、智擎依舊受青睞。法人表示，目前市場盛傳以新藥股的新藥代號來「解盲」股價，浩鼎明年2月底前將公布數據的乳癌新藥OBI-822，股價有上看822元機會；中裕的TMB-355，表示股價可望來到355元，因此，智擎的胰臟癌新藥MM-398，也暗示股價有挑戰398元實力。另外，基亞的PI-88，就是數字不佳，去年因三期數據不如預期，股價最低時也摜破88元。如果照這種數字密碼解讀，那麼最吃香的是藥華藥用於治療真性紅血球增生症（PV）的P1101，數字是4位數！法人表示，生醫股挾著總統牌和尹衍樑將持續加碼投資的雙重利多效應，產業前景多頭趨勢不變，股價走勢也將是緩步上攻小回格局，為了蘊釀產業進入國際藥廠和投資機構的雷達區內，預期明年上半年以前，一定會有一、二檔股票有機會上看1千元，數據解盲成功或授權公司都會是標的。(工商時報)
順藥 新董監(林榮錦/鄭萬來/李忠良/謝德夫/蔡長海/李聖婉/陳慶(方方土))
順藥：公告本公司105年第一次股東臨時會全面改選董監事，董事變動已達1/3 鉅亨網／鉅亨網新聞中心-2016年01月26日第三十四條 第6款1.發生變動日期:105/01/262.舊任者姓名及簡歷:董事：晟德大藥廠股份有限公司 代表人：林榮錦/晟德大藥廠股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：李忠良/高林實業股份有限公司董事暨執行長董事：晟德大藥廠股份有限公司 代表人：陳俊宏/中天生物科技股份有限公司董事董事：安基生醫股份有限公司董事：鄭萬來/永彰機電股份有限公司董事長董事：順晟藥品有限公司 代表人：謝德夫/班友投資股份公司董事長董事：晟信投資顧問有限公司3.新任者姓名及簡歷:董事：晟德大藥廠股份有限公司 代表人：林榮錦/晟德大藥廠股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：鄭萬來/永彰機電股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：李忠良/高林實業股份有限公司董事暨執行長董事：順晟藥品有限公司 代表人：謝德夫/班友投資股份公司董事長董事：蔡長海/中國醫藥大學暨醫療體系董事長獨立董事：李聖婉/華聯生物科技股份有限公司總顧問；生揚管理顧問股份有限公司創辦人/總經理；生揚創業投資股份有限公司創辦人/總經理獨立董事：陳慶(方方土)/嘉信聯合會計師事務所合夥會計師4.異動情形（請輸入「辭職」、「解任」、「任期屆滿」或「新任」）:新任5.異動原因:全面改選6.新任董事選任時持股數:晟德大藥廠股份有限公司:26,742,000股順晟藥品有限公司：1,000股蔡長海：419,000股李聖婉：0股陳慶(方方土)：0股7.原任期（例xx/xx/xx至xx/xx/xx）:103/07/25~106/07/248.新任生效日期:105/01/269.同任期董事變動比率:6/710.其他應敘明事項:無
到宅醫師通過 漸凍人病友不凍!!
用愛「解凍」！醫師到宅服務送愛 【華人健康網 記者洪毓琪／台北報導】 2016年1月26日用愛「解凍」！對於罹患罕見疾病的漸凍人病友來說，不僅生活起居因肌肉萎縮而受限，生病就醫更是不便。所幸，在台北市立聯合醫院忠孝院區「居家醫療」照護「醫師到宅」服務的推行下，如今漸凍人病友即使不出門，也能得到妥善、健全的醫療照護，重新找回自我尊嚴。 台北市立聯合醫院忠孝院區葉啟昌副院長表示，生、老、病、死是萬物不變的定律，人類也是，不管你是貧，或是富，都早晚要面對它，經濟能力好的，就能自行處理；但經濟條件差的人，就有待社會各界，乃至政府來照料，做到「全人關懷，弱勢先行」的境界。自從台北市成立聯合醫院以來，過去各自為政，浪費醫療資源的現象已達到改善。且在資訊與採購方面的整合下，不僅有效提升市民就醫的便利性，更讓醫療品質有所進步。近年來，聯合醫院積極走入社區，落實社區型醫院的角色，推動家庭責任醫師制度，同時開展家戶關懷行動。化被動為主動！聯醫提供「醫師到宅」服務在104年度4月「醫療型家庭醫師責任制度」草案通過後，台北市立聯合醫院忠孝院區有感受在家醫制度的落實上，不能只靠深耕地方的診所基層醫師努力，社區醫院更是責無旁貸。有鑑於此，台北市立聯合醫院忠孝院區從104年度，便嘗試醫院功能行動化，化被動為主動，提供「醫師到宅」服務，直接將醫療服務直接送入有需求的民眾家中。